DSM-Firmenich reportedly nears deal with CVC for animal nutrition business

The global chemical and nutrition giant DSM-Firmenich is reportedly in advanced negotiations with private equity firm CVC Capital Partners regarding the divestment of its animal nutrition and health business. This potential transaction marks a pivotal shift for the Swiss-Dutch company as it seeks to streamline its portfolio and sharpen its focus on high-growth segments such as perfumery, beauty, and human nutrition. The move comes following the massive €21 billion merger between DSM and Firmenich, which was finalized last year, creating a new leader in the flavor and fragrance industry. Industry analysts estimate the valuation of the animal nutrition division to be significant, given its position as one of the world's leading suppliers of vitamins, premixes, and feed additives for livestock and aquaculture. However, the business has recently faced strong headwinds, including high inventory levels and volatile pricing in the global vitamin market, particularly impacting its profitability. By offloading this capital-intensive unit, DSM-Firmenich aims to reduce its exposure to these cyclical commodity fluctuations and satisfy investor demands for more stable and resilient margins. CVC Capital Partners, a seasoned player in the private equity space with a history of acquiring industrial and healthcare assets, appears to be the frontrunner in a competitive bidding process. While neither party has officially confirmed the final terms of the deal, sources close to the matter suggest that an announcement could be imminent. If successful, the acquisition would allow CVC to leverage its operational expertise to revitalize the animal health unit as a standalone entity, while DSM-Firmenich would use the proceeds to strengthen its balance sheet and invest further into its core consumer-facing segments.